Patents by Inventor Carlos J. Gimeno

Carlos J. Gimeno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020115140
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS (“regulator of G-protein signalling”) gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Application
    Filed: June 4, 2001
    Publication date: August 22, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 6399760
    Abstract: The present invention, which is based on the discovery of novel genes encoding rp polypeptides, features therapeutics, diagnostics and screening assays.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: June 4, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Patrick W. Kleyn, Karen J. Moore
  • Patent number: 6291177
    Abstract: The invention relates to a novel transformed yeast cell comprising a first heterologous nucleic acid sequence encoding a G-protein coupled receptor; and second nucleic acid sequence encoding the yeast G&agr; subunit protein Gpa2; and an optional third heterologous nucleic acid sequence encoding a reporter protein. The G-protein coupled receptor can bind ligand thereby altering the activity of Gpa2 and cellular levels of second messenger molecules and ultimately the activity of target genes. The transformed yeast cell can be used, for example, in in vitro high throughput assays to screen for agonists and antagonists of G-protein coupled receptor ligand activity.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: September 18, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kevin T. Madden, Patrick R. Errada, Carlos J. Gimeno
  • Patent number: 6280934
    Abstract: The invention relates to a novel transformed yeast cell comprising a first heterologous nucleic acid sequence encoding a G-protein coupled receptor; and second nucleic acid sequence encoding the yeast G&agr; subunit protein Gpa2; and an optional third heterologous nucleic acid sequence encoding a reporter protein. The G-protein coupled receptor can bind ligand thereby altering the activity of Gpa2 and cellular levels of second messenger molecules and ultimately the activity of target genes. The transformed yeast cell can be used, for example, in in vitro high throughput assays to screen for agonists and antagonists of G-protein coupled receptor ligand activity.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: August 28, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kevin T. Madden, Patrick R. Errada, Carlos J. Gimeno
  • Patent number: 6146827
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: November 14, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 6147192
    Abstract: The present invention provides a novel tub interactor (TI) polypeptides, as well as TI fusion polypeptides, and antigenic peptides.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: November 14, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Patrick R. Errada
  • Patent number: 6031076
    Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: February 29, 2000
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Carlos J. Gimeno
  • Patent number: 6020142
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: February 1, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 6008014
    Abstract: The present invention relates to the discovery of novel genes encoding Lipid Metabolic Pathway (LMP) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: December 28, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Susan Acton
  • Patent number: 5955306
    Abstract: The present invention relates to the discovery of novel genes encoding Tub interactor (TI) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: September 21, 1999
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Patrick R. Errada
  • Patent number: 5948639
    Abstract: The invention provides isolated nucleic acids molecules, designated EMI1 nucleic acid molecules, which encode proteins involved in growth factor, e.g., TGF-.beta., cell signaling. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing EMI1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an EMI1 gene has been introduced or disrupted. The invention still further provides isolated EMI1 proteins, fusion proteins, antigenic peptides and anti-EMI1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: September 7, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Dean A. Falb
  • Patent number: 5846780
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules and proteins encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian R11 gene, including the human R11 gene. R11 sequence analysis indicates that the R11 gene is a novel gene belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: December 8, 1998
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 5807708
    Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: September 15, 1998
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Carlos J. Gimeno